Clinical Trials
2 trialsNCT03086681 2025-07-29
ECWHCCFLACC
First Affiliated Hospital of Guangxi Medical University
Phase 2 Completed
NCT06617936 2025-07-15
Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.
Shandong Public Health Clinical Center
Phase 2 Recruiting